ID   HTRA1_HUMAN             Reviewed;         480 AA.
AC   Q92743; D3DRE4; Q9UNS5;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1997, sequence version 1.
DT   21-MAR-2012, entry version 116.
DE   RecName: Full=Serine protease HTRA1;
DE            EC=3.4.21.-;
DE   AltName: Full=High-temperature requirement A serine peptidase 1;
DE   AltName: Full=L56;
DE   AltName: Full=Serine protease 11;
DE   Flags: Precursor;
GN   Name=HTRA1; Synonyms=HTRA, PRSS11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   MEDLINE=97131593; PubMed=8977104; DOI=10.1016/S0014-5793(96)01229-X;
RA   Zumbrunn J., Trueb B.;
RT   "Primary structure of a putative serine protease specific for IGF-
RT   binding proteins.";
RL   FEBS Lett. 398:187-192(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Crowl R.M., Luk D., Milnamow M.;
RT   "Genomic organization and promoter characterization of the human HTRA
RT   (PRSS11) gene.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 144-480, PROTEIN SEQUENCE OF 33-44,
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   SER-328.
RC   TISSUE=Cartilage;
RX   MEDLINE=99069438; PubMed=9852107; DOI=10.1074/jbc.273.51.34406;
RA   Hu S.I., Carozza M., Klein M., Nantermet P., Luk D., Crowl R.M.;
RT   "Human HtrA, an evolutionarily conserved serine protease identified as
RT   a differentially expressed gene product in osteoarthritic cartilage.";
RL   J. Biol. Chem. 273:34406-34412(1998).
RN   [5]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=15208355; DOI=10.1369/jhc.3A6186.2004;
RA   De Luca A., De Falco M., Fedele V., Cobellis L., Mastrogiacomo A.,
RA   Laforgia V., Tuduce I.L., Campioni M., Giraldi D., Paggi M.G.,
RA   Baldi A.;
RT   "The serine protease HtrA1 is upregulated in the human placenta during
RT   pregnancy.";
RL   J. Histochem. Cytochem. 52:885-892(2004).
RN   [6]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16377621; DOI=10.1074/jbc.M500361200;
RA   Grau S., Richards P.J., Kerr B., Hughes C., Caterson B.,
RA   Williams A.S., Junker U., Jones S.A., Clausen T., Ehrmann M.;
RT   "The role of human HtrA1 in arthritic disease.";
RL   J. Biol. Chem. 281:6124-6129(2006).
RN   [7]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ARMD7.
RX   PubMed=17053108; DOI=10.1126/science.1133807;
RA   Dewan A., Liu M., Hartman S., Zhang S.S.-M., Liu D.T.L., Zhao C.,
RA   Tam P.O.S., Chan W.M., Lam D.S.C., Snyder M., Barnstable C.,
RA   Pang C.P., Hoh J.;
RT   "HTRA1 promoter polymorphism in wet age-related macular
RT   degeneration.";
RL   Science 314:989-992(2006).
RN   [8]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ARMD7.
RX   PubMed=17053109; DOI=10.1126/science.1133811;
RA   Yang Z., Camp N.J., Sun H., Tong Z., Gibbs D., Cameron D.J., Chen H.,
RA   Zhao Y., Pearson E., Li X., Chien J., DeWan A., Harmon J.,
RA   Bernstein P.S., Shridhar V., Zabriskie N.A., Hoh J., Howes K.,
RA   Zhang K.;
RT   "A variant of the HTRA1 gene increases susceptibility to age-related
RT   macular degeneration.";
RL   Science 314:992-993(2006).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20671064; DOI=10.1158/1541-7786.MCR-09-0473;
RA   Campioni M., Severino A., Manente L., Tuduce I.L., Toldo S.,
RA   Caraglia M., Crispi S., Ehrmann M., He X., Maguire J., De Falco M.,
RA   De Luca A., Shridhar V., Baldi A.;
RT   "The serine protease HtrA1 specifically interacts and degrades the
RT   tuberous sclerosis complex 2 protein.";
RL   Mol. Cancer Res. 8:1248-1260(2010).
RN   [10]
RP   STRUCTURE BY NMR OF 367-480.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the PDZ-domain of human protease HTRA 1
RT   precursor.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 158-480, HOMOTRIMERIZATION,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-328.
RX   PubMed=21297635; DOI=10.1038/nsmb.2013;
RA   Truebestein L., Tennstaedt A., Monig T., Krojer T., Canellas F.,
RA   Kaiser M., Clausen T., Ehrmann M.;
RT   "Substrate-induced remodeling of the active site regulates human HTRA1
RT   activity.";
RL   Nat. Struct. Mol. Biol. 18:386-388(2011).
RN   [12]
RP   VARIANTS CARASIL THR-252 AND MET-297, AND CHARACTERIZATION OF VARIANTS
RP   CARASIL THR-252 AND MET-297.
RX   PubMed=19387015; DOI=10.1056/NEJMoa0801560;
RA   Hara K., Shiga A., Fukutake T., Nozaki H., Miyashita A., Yokoseki A.,
RA   Kawata H., Koyama A., Arima K., Takahashi T., Ikeda M., Shiota H.,
RA   Tamura M., Shimoe Y., Hirayama M., Arisato T., Yanagawa S., Tanaka A.,
RA   Nakano I., Ikeda S., Yoshida Y., Yamamoto T., Ikeuchi T., Kuwano R.,
RA   Nishizawa M., Tsuji S., Onodera O.;
RT   "Association of HTRA1 mutations and familial ischemic cerebral small-
RT   vessel disease.";
RL   N. Engl. J. Med. 360:1729-1739(2009).
CC   -!- FUNCTION: Serine protease with a variety of targets, including
CC       extracellular matrix proteins such as fibronectin. HTRA1-generated
CC       fibronectin fragments further induce synovial cells to up-regulate
CC       MMP1 and MMP3 production. May also degrade proteoglycans, such as
CC       aggrecan, decorin and fibromodulin. Through cleavage of
CC       proteoglycans, may release soluble FGF-glycosaminoglycan complexes
CC       that promote the range and intensity of FGF signals in the
CC       extracellular space. Regulates the availability of insulin-like
CC       growth factors (IGFs) by cleaving IGF-binding proteins. Inhibits
CC       signaling mediated by TGF-beta family members. This activity
CC       requires the integrity of the catalytic site, although it is
CC       unclear whether TGF-beta proteins are themselves degraded. By
CC       acting on TGF-beta signaling, may regulate many physiological
CC       processes, including retinal angiogenesis and neuronal survival
CC       and maturation during development. Intracellularly, degrades TSC2,
CC       leading to the activation of TSC2 downstream targets.
CC   -!- SUBUNIT: Forms homotrimers. In the presence of substrate, may form
CC       higher-order multimers in a PDZ-independent manner. Interacts with
CC       TGF-beta family members, including BMP4, TGFB1, TGFB2, activin A
CC       and GDF5 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Secreted. Cytoplasm, cytosol.
CC       Note=Predominantly secreted. Also found associated with the plasma
CC       membrane.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with strongest expression in
CC       placenta (at protein level). Secreted by synovial fibroblasts. Up-
CC       regulated in osteoarthritis and rheumatoid arthritis synovial
CC       fluids and cartilage as compared with non-arthritic (at protein
CC       level).
CC   -!- DEVELOPMENTAL STAGE: In the placenta, in the first trimester of
CC       gestation, low expression in the cells surrounding villi both in
CC       the inner layer of the cytotrophoblast and in the outer layer of
CC       the syncytiotrophoblast (at protein level). In the third trimester
CC       of gestation, very strong expression in the outer layer forming
CC       the syncytiotrophoblast and lower in the cytotrophoblast (at
CC       protein level).
CC   -!- DOMAIN: The IGFBP N-terminal domain mediates interaction with TSC2
CC       substrate.
CC   -!- DISEASE: Variations in the promoter region of HTRA1 are the cause
CC       of susceptibility to age-related macular degeneration type 7
CC       (ARMD7) [MIM:610149]. ARMD is the leading cause of vision loss and
CC       blindness among older individuals in the developed word. It is
CC       classified as either dry (nonneovascular) or wet (neovascular).
CC       ARMD7 is a wet form, in which new blood vessels form and break
CC       beneath the retina. This leakage causes permanent damage to
CC       surrounding retinal tissue, distorting and destroying central
CC       vision. Wet ARMD is more prevalent among Asians than Caucasians.
CC   -!- DISEASE: Defects in HTRA1 are the cause of cerebral autosomal
CC       recessive arteriopathy with subcortical infarcts and
CC       leukoencephalopathy (CARASIL) [MIM:600142]. CARASIL is
CC       characterized by nonhypertensive cerebral small-vessel
CC       arteriopathy with subcortical infarcts, alopecia, and spondylosis,
CC       with an onset in early adulthood. On neuropathological
CC       examination, atherosclerosis associated with intimal thickening
CC       and dense collagen fibers, loss of vascular smooth-muscle cells,
CC       and hyaline degeneration of the tunica media has been observed in
CC       cerebral small arteries.
CC   -!- SIMILARITY: Belongs to the peptidase S1B family.
CC   -!- SIMILARITY: Contains 1 IGFBP N-terminal domain.
CC   -!- SIMILARITY: Contains 1 Kazal-like domain.
CC   -!- SIMILARITY: Contains 1 PDZ (DHR) domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/HTRA1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y07921; CAA69226.1; -; mRNA.
DR   EMBL; AF157623; AAD41525.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49312.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49313.1; -; Genomic_DNA.
DR   EMBL; AF097709; AAC97211.1; -; mRNA.
DR   IPI; IPI00003176; -.
DR   RefSeq; NP_002766.1; NM_002775.4.
DR   UniGene; Hs.501280; -.
DR   PDB; 2JOA; NMR; -; A=380-480.
DR   PDB; 2YTW; NMR; -; A=370-480.
DR   PDB; 3NUM; X-ray; 2.75 A; A=158-480.
DR   PDB; 3NWU; X-ray; 3.20 A; A/B/C=158-375.
DR   PDB; 3NZI; X-ray; 2.75 A; A=158-480.
DR   PDBsum; 2JOA; -.
DR   PDBsum; 2YTW; -.
DR   PDBsum; 3NUM; -.
DR   PDBsum; 3NWU; -.
DR   PDBsum; 3NZI; -.
DR   ProteinModelPortal; Q92743; -.
DR   SMR; Q92743; 51-480.
DR   DIP; DIP-33195N; -.
DR   IntAct; Q92743; 5.
DR   MINT; MINT-1198897; -.
DR   STRING; Q92743; -.
DR   MEROPS; S01.277; -.
DR   DMDM; 18202620; -.
DR   PeptideAtlas; Q92743; -.
DR   PRIDE; Q92743; -.
DR   DNASU; 5654; -.
DR   Ensembl; ENST00000368984; ENSP00000357980; ENSG00000166033.
DR   GeneID; 5654; -.
DR   KEGG; hsa:5654; -.
DR   UCSC; uc001lgj.2; human.
DR   CTD; 5654; -.
DR   GeneCards; GC10P124221; -.
DR   H-InvDB; HIX0009274; -.
DR   HGNC; HGNC:9476; HTRA1.
DR   HPA; HPA036655; -.
DR   MIM; 600142; phenotype.
DR   MIM; 602194; gene.
DR   MIM; 610149; phenotype.
DR   neXtProt; NX_Q92743; -.
DR   Orphanet; 279; Age-related macular degeneration.
DR   Orphanet; 199354; CARASIL syndrome.
DR   PharmGKB; PA33829; -.
DR   eggNOG; COG0265; -.
DR   GeneTree; ENSGT00510000046315; -.
DR   HOGENOM; HBG585708; -.
DR   HOVERGEN; HBG052044; -.
DR   InParanoid; Q92743; -.
DR   KO; K08784; -.
DR   OMA; GNNTVEL; -.
DR   OrthoDB; EOG4KH2V3; -.
DR   PhylomeDB; Q92743; -.
DR   NextBio; 21974; -.
DR   ArrayExpress; Q92743; -.
DR   Bgee; Q92743; -.
DR   CleanEx; HS_HTRA1; -.
DR   Genevestigator; Q92743; -.
DR   GermOnline; ENSG00000166033; Homo sapiens.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0005520; F:insulin-like growth factor binding; IEA:InterPro.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   GO; GO:0001558; P:regulation of cell growth; IEA:InterPro.
DR   InterPro; IPR000867; IGFBP-like.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR009003; Pept_cys/ser_Trypsin-like.
DR   InterPro; IPR001940; Peptidase_S1C.
DR   InterPro; IPR002350; Prot_inh_Kazal.
DR   InterPro; IPR011497; Prot_Inh_Kazal_2.
DR   Pfam; PF00219; IGFBP; 1.
DR   Pfam; PF07648; Kazal_2; 1.
DR   Pfam; PF00595; PDZ; 1.
DR   PRINTS; PR00834; PROTEASES2C.
DR   SMART; SM00121; IB; 1.
DR   SMART; SM00280; KAZAL; 1.
DR   SMART; SM00228; PDZ; 1.
DR   SUPFAM; SSF50156; PDZ; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51323; IGFBP_N_2; 1.
DR   PROSITE; PS51465; KAZAL_2; 1.
DR   PROSITE; PS50106; PDZ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Age-related macular degeneration; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation;
KW   Growth factor binding; Hydrolase; Protease; Reference proteome;
KW   Secreted; Serine protease; Signal.
FT   SIGNAL        1     22       Potential.
FT   CHAIN        23    480       Serine protease HTRA1.
FT                                /FTId=PRO_0000026943.
FT   DOMAIN       33    100       IGFBP N-terminal.
FT   DOMAIN       98    157       Kazal-like.
FT   DOMAIN      365    467       PDZ.
FT   REGION      204    364       Serine protease.
FT   ACT_SITE    220    220       Charge relay system (Potential).
FT   ACT_SITE    250    250       Charge relay system (Potential).
FT   ACT_SITE    328    328       Charge relay system.
FT   SITE        169    169       Involved in trimer stabilization.
FT   SITE        171    171       Involved in trimer stabilization.
FT   SITE        278    278       Involved in trimer stabilization.
FT   VARIANT     252    252       A -> T (in CARASIL; has 21 to 50% normal
FT                                protease activity; is unable to suppress
FT                                TGF-beta activity; dbSNP:rs113993968).
FT                                /FTId=VAR_063148.
FT   VARIANT     297    297       V -> M (in CARASIL; has 21 to 50% normal
FT                                protease activity; is unable to suppress
FT                                TGF-beta activity; dbSNP:rs113993969).
FT                                /FTId=VAR_063149.
FT   MUTAGEN     328    328       S->A: Loss of activity.
FT   CONFLICT    323    323       I -> T (in Ref. 4; AAC97211).
FT   STRAND      384    389
FT   HELIX       392    401
FT   STRAND      411    417
FT   STRAND      419    421
FT   HELIX       422    426
FT   HELIX       445    454
FT   STRAND      456    464
FT   STRAND      467    473
SQ   SEQUENCE   480 AA;  51287 MW;  CA20A99480FB2330 CRC64;
     MQIPRAALLP LLLLLLAAPA SAQLSRAGRS APLAAGCPDR CEPARCPPQP EHCEGGRARD
     ACGCCEVCGA PEGAACGLQE GPCGEGLQCV VPFGVPASAT VRRRAQAGLC VCASSEPVCG
     SDANTYANLC QLRAASRRSE RLHRPPVIVL QRGACGQGQE DPNSLRHKYN FIADVVEKIA
     PAVVHIELFR KLPFSKREVP VASGSGFIVS EDGLIVTNAH VVTNKHRVKV ELKNGATYEA
     KIKDVDEKAD IALIKIDHQG KLPVLLLGRS SELRPGEFVV AIGSPFSLQN TVTTGIVSTT
     QRGGKELGLR NSDMDYIQTD AIINYGNSGG PLVNLDGEVI GINTLKVTAG ISFAIPSDKI
     KKFLTESHDR QAKGKAITKK KYIGIRMMSL TSSKAKELKD RHRDFPDVIS GAYIIEVIPD
     TPAEAGGLKE NDVIISINGQ SVVSANDVSD VIKRESTLNM VVRRGNEDIM ITVIPEEIDP
//
